BioCentury
ARTICLE | Distillery Therapeutics

Cancer

January 17, 2018 7:29 PM UTC

Cell culture and mouse studies suggest inhibiting SLC7A5 or SLC43A1 could help treat MYC-driven neuroblastoma and Burkitt’s lymphoma. In MYC-driven human neuroblastoma and Burkitt’s lymphoma cell lines, shRNA targeting SLC7A5 or SLC43A1 decreased proliferation and increased apoptosis compared with non-specific shRNA. In xenograft mouse models of MYC-driven neuroblastoma and Burkitt’s lymphoma, tumor-specific knockdown of SLC7A5 or SLC43A1 decreased tumor growth compared with normal expression. Next steps could include identifying and testing inhibitors of SLC7A5 or SLC43A1 in models of MYC-driven neuroblastoma and Burkitt’s lymphoma...